Cargando…
Interleukin-6, a reliable prognostic factor for ischemic stroke
Background:Interleukin-6 (IL-6) is one of the inflammatory mediators characterized by elevated levels in ischemic stroke (IS) patients. The present study set out to assess the role of IL-6, as a marker for inflammation, in the severity and prognosis of acute IS. Methods:In a cross-sectional descript...
Autores principales: | Shaafi, Sheyda, Sharifipour, Ehsan, Rahmanifar, Rouhollah, Hejazi, SeyedShamseddin, Andalib, Sasan, Nikanfar, Masoud, Baradarn, Behzad, Mehdizadeh, Robab |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Iranian Neurological Association
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187333/ https://www.ncbi.nlm.nih.gov/pubmed/25295149 |
Ejemplares similares
-
Optic coherence tomography findings in relapsing-remitting multiple sclerosis patients of the northwest of Iran
por: Talebi, Mahnaz, et al.
Publicado: (2013) -
A comparison of risk factors and severity of ischemic stroke in female and male genders in North-West Iran: A cross-sectional study
por: Talebi, Mahnaz, et al.
Publicado: (2014) -
Exploring potential serum levels of Homocysteine, interleukin‐1 beta, and apolipoprotein B 48 as new biomarkers for patients with ischemic stroke
por: Shademan, Behrouz, et al.
Publicado: (2021) -
Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial
por: Khani, Samira, et al.
Publicado: (2021) -
Effect of Whey Protein Supplementation on Inflammatory and Antioxidant Markers, and Clinical Prognosis in Acute Ischemic Stroke (TNS Trial): A Randomized, Double Blind, Controlled, Clinical Trial
por: Hashemilar, Mazyar, et al.
Publicado: (2020)